Enterobacteriaceae against Carbapenem-Resistant Therapies Tigecycline-Colistin Combination Activities of In Vivo and In Vitro

[1]  E. Alp,et al.  Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination , 2014, Journal of chemotherapy.

[2]  P. Coote,et al.  Evaluation of Galleria mellonella larvae for measuring the efficacy and pharmacokinetics of antibiotic therapies against Pseudomonas aeruginosa infection. , 2014, International journal of antimicrobial agents.

[3]  D. Wareham,et al.  In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens. , 2013, International journal of antimicrobial agents.

[4]  M. Falagas,et al.  Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence , 2013, Antimicrobial Agents and Chemotherapy.

[5]  A. Tsakris,et al.  Activity of Tigecycline in Combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-Producing Enterobacteriaceae in a Murine Thigh Infection Model , 2013, Antimicrobial Agents and Chemotherapy.

[6]  R. Humphries,et al.  Colistin MIC Variability by Method for Contemporary Clinical Isolates of Multidrug-Resistant Gram-Negative Bacilli , 2013, Journal of Clinical Microbiology.

[7]  M. Sunbul,et al.  Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. , 2012, International journal of antimicrobial agents.

[8]  J. Pagés,et al.  Membrane permeability, a pivotal function involved in antibiotic resistance and virulence in Enterobacter aerogenes clinical isolates. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  K. Bowker,et al.  Bactericidal Activity of Multiple Combinations of Tigecycline and Colistin against NDM-1-Producing Enterobacteriaceae , 2012, Antimicrobial Agents and Chemotherapy.

[10]  P. Nordmann,et al.  Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. , 2012, International journal of antimicrobial agents.

[11]  D. Paterson,et al.  Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens , 2012, Antimicrobial Agents and Chemotherapy.

[12]  J. Li,et al.  Dosing of colistin-back to basic PK/PD. , 2011, Current opinion in pharmacology.

[13]  L. Leibovici,et al.  Efficacy and safety of tigecycline: a systematic review and meta-analysis. , 2011, The Journal of antimicrobial chemotherapy.

[14]  M. Falagas,et al.  Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. , 2011, Future microbiology.

[15]  Neil Woodford,et al.  What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. , 2011, International journal of antimicrobial agents.

[16]  N. Gordon,et al.  In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. , 2011, The Journal of antimicrobial chemotherapy.

[17]  S. Pournaras,et al.  Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. , 2011, International journal of antimicrobial agents.

[18]  N. Gordon,et al.  Potent Synergy and Sustained Bactericidal Activity of a Vancomycin-Colistin Combination versus Multidrug-Resistant Strains of Acinetobacter baumannii , 2010, Antimicrobial Agents and Chemotherapy.

[19]  N. Woodford,et al.  Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study , 2010, The Lancet. Infectious diseases.

[20]  J. Quinn,et al.  AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. , 2010, The Journal of antimicrobial chemotherapy.

[21]  I. Gould,et al.  Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. , 2010, The Journal of antimicrobial chemotherapy.

[22]  Susan E. Brown,et al.  A peptidomics study reveals the impressive antimicrobial peptide arsenal of the wax moth Galleria mellonella. , 2009, Insect biochemistry and molecular biology.

[23]  I. Cooper,et al.  Galleria mellonella as an alternative infection model for Yersinia pseudotuberculosis. , 2009, Microbiology.

[24]  J. Li,et al.  In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. , 2007, The Journal of antimicrobial chemotherapy.

[25]  D. Wareham,et al.  In Vitro Activities of Polymyxin B, Imipenem, and Rifampin against Multidrug-Resistant Acinetobacter baumannii , 2006, Antimicrobial Agents and Chemotherapy.

[26]  J. Turnidge,et al.  Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. , 2005, International journal of antimicrobial agents.

[27]  F. Ausubel,et al.  Positive Correlation between Virulence ofPseudomonas aeruginosa Mutants in Mice and Insects , 2000, Journal of bacteriology.

[28]  M. Vaara,et al.  Agents that increase the permeability of the outer membrane. , 1992, Microbiological reviews.